Therapeutic landscape of advanced HER2-positive breast cancer in 2022-Reference-Cited by-同舟云学术

Therapeutic landscape of advanced HER2-positive breast cancer in 2022

Published:2022-10-12 Issue:12 Volume:39 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Gupta Ruby^ORCID,Gupta Sachin,Antonios Bana,Ghimire Bipin,Jindal Vishal,Deol Jaskiran,Gaikazian Suzanna,Huben Marianne,Anderson Joseph,Stender Michael,Jaiyesimi Ishmael

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12032-022-01849-y.pdf

Reference65 articles.

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

2. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–74.

3. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.

4. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34.

5. Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;4:519–30.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiotracer Innovations in Breast Cancer Imaging: A Review of Recent Progress;Diagnostics;2024-09-03

2. Overexpression of cytoplasmic poly(A)-binding protein 1 as a biomarker for the prognosis and selection of postoperative regimen in breast cancer;Clinical and Translational Oncology;2024-08-22

3. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials;Critical Reviews in Oncology/Hematology;2024-04

4. Meta-analysis of the clinical efficacy and safety of T-DM1 in the treatment of HER2-positive breast cancer;Indian Journal of Cancer;2024-01

5. Overexpression of antiapoptotic gene products and resistance to trastuzumab treatment of breast cancer;Overcoming Cancers Resistant to HER-2 Antibodies;2024